NCT02766140终止3 期
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination with docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with SHR1020 in combination with docetaxel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age:18-70 years
- •Histologically or cytologically confirmed locally advanced and/or metastatic NSCLC or recurrent NSCLC (≤9 months from date of diagnosis to randomized ), epidermal growth factor receptor-wild type, Anaplastic Lymphoma Kinase-wild type or unknown mutation
- •At least one lesion that can be accurately measured and has not been received local treatments such as radiotherapy and cryotherapy
- •Relapse or failure of one first line prior platinum-based chemotherapy
- •Eastern Cooperative Oncology Group performance status 0 or 1
- •Life expectancy of at least 12 weeks
- •Adequate organ and bone marrow function as defined below(no blood transfusion or drugs for leucopenia and Platelet within 14 days before screening): (1) HB≥90g/l (2) ANC≥1.5×10^9/l (3) PLT≥100×10^9/l (4) BIL<1.25×upper limit of normal (5) Alanine Aminotransferase and/or AST<2.5×upper limit of normal (< 5×upper limit of normal for patients with liver metastasis) (6) Cr≤1.25×upper limit of normal or Creatinine clearance rate>45ml/min ( Cockcroft-Gault Formula) (7) Cholesterol≤1.5×upper limit of normal, Triglyceride≤2.5×upper limit of normal (8) Left ventricular ejection fraction (LVEF) greater than lower limit of normal
- •Female: child bearing potential, a negative urine or serum pregnancy test result within 7 days before randomisation, agree to use effective contraception while on treatment and for at least 6 months after end of treatment;male: agree to use effective contraception while on treatment and for at least 6 months after end of treatment
- •Patient has given written informed consent
排除标准
- •More than one prior chemotherapy regimen for advanced and/or metastatic or recurrent NSCLC (except neoadjuvant or adjuvant chemotherapy )
- •Previous therapy with other VEGFR inhibitors、recombinant human endostatin、 docetaxel or immunotherapy for treatment of NSCLC
- •History of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80), Hypersensitivity to the excipients of the trial drugs or contrast medium
- •Have clinically significant cavity effusion,such as pleural effusion、 pericardial effusion or ascites and require clinical intervention
- •Active brain metastases
- •Other malignancy within the past (including primary brain tumor or Leptomeningeal tumor), other than basal cell skin cancer or carcinoma in situ of the cervix
- •Significant weight loss (>10%) within the past 6 weeks
- •Persistence of clinically relevant therapy related toxicities from previous therapy (greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1)
- •Treatment with surgery, chemotherapy, hormone therapy, radiotherapy, immunomodulation or monoclonal antibody therapy within the past 4 weeks and traditional chinese medicine for antitumor therapy within the past 2 weeks before start of therapy
- •Radiographical evidence of cavitary or necrotic tumours
- •Centrally located tumours with radiographical evidence (CT or MRI) of local invasion of major blood vessels
- •Greater than CTCAE 4.0 grade 2 pulmonary hemorrhage within the past one month before screening
- •History of clinically significant haemoptysis within the past 3 months (more than half a teaspoon within 24 hours )
- •History of major thrombotic or clinically relevant major bleeding event in the past 6 months
- •Prothrombin time (PT) and/or partial thromboplastin time (PTT) > 50% of devi
- •ation of upper limit of normal
- •Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogus, if INR≤1.5, with the purpose of prevention,the use of low-dose warfarin (1mg, qd) or aspirin ( ≤ 100 mg per day ) is allowed
- •Incomplete wound healing or fracture for long time
- •Uncontrolled hypertensin with one antihypertensive agent, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure>NYHA II, serious cardiac arrhythmia
- •Urinary protein≥++ and confirmed 24-hour urinary protein greater than 1.0g;
- •Preexisting thyroid dysfunction, even with medical therapy, thyroid function can not be maintained in the normal range
- •Uncontrolled diabetes mellitus with antidiabetic therapy
- •Current peripheral neuropathy greater than CTCAE 4.0 grade 2
- •Active or chronic hepatitis C and/or B infection with liver dysfunction
- •History of immunodeficiency diseases, other acquired or congenital immunodeficiency diseases, or history of organ transplantation
- •Serious infections requiring systemic antibiotic therapy
- •Variety of factors that affect the oral medication (such as unable to swallow, chronic diarrhea, bowel obstruction and other gastrointestinal disorders or abnormalities
- •Pregnancy or breast feeding
- •Active alcohol or drug abuse
- •Treatment in another clinical trial within the past 4 weeks before start of therapy
- •Psychological, familial, sociological, or geographical factors potentially hampering compliance with the study protocol and follow-up schedule
- •According to the investigator, other conditions that may increase the risk associated with patient safety and study participation
研究组 & 干预措施
SHR1020 plus Docetaxel
Experimental
干预措施: SHR1020 plus Docetaxel (Drug)
Placebo plus Docetaxel
Placebo Comparator
干预措施: Placebo plus Docetaxel (Drug)
结局指标
主要结局
Overall Survival
时间窗: approximately 30 months
次要结局
- Objective Tumour Response (Complete Response Plus Partial Response) Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1(approximately 30months)
- Disease Control (Complete Response Plus Partial Response plus stable disease) Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1(approximately 30months)
- Progression Free Survival (PFS)(approximately 30 months)
- Quality of Life (QoL) measured by standardised questionnaires (EORTC Quality of Life Questionnaire-C30)(approximately 30months)
- Incidence and Intensity of Adverse Events(From signing informed consent document until 30 days after the last drug administration)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPCProstate Cancer MetastaticNCT04603833Jiangsu HengRui Medicine Co., Ltd.150
已完成
3 期
Docetaxel in Breast CancerBreast CancerNCT00312208Sanofi3,299
已完成
2 期
Docetaxel in Treating Patients With Persistent or Recurrent Cervical CancerCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedRecurrent Cervical CarcinomaNCT00041093Gynecologic Oncology Group27
Unknown
2 期
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid TumorsSolid TumorsNon-small Cell Lung CancerGastric CancerBreast CancerProstate CancerNCT01803503National University Hospital, Singapore80
已完成
3 期
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal CancerAdvanced Esophageal CancerNCT03691090Jiangsu HengRui Medicine Co., Ltd.596